Sign In
Buy BIAF
$0.627
-0.0170 (-2.64%)
At Close: Jul 31, 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF publishes CyPath Lung white paper which presents clinical protocols for lung nodule evaluation, lung cancer patient care & survivor surveillance.
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
10:06am, Friday, 24'th Jul 2026
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD
08:08am, Wednesday, 22'nd Jul 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment.
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
01:23am, Wednesday, 22'nd Jul 2026
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
02:37pm, Thursday, 09'th Jul 2026
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
08:46am, Tuesday, 07'th Jul 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
02:54pm, Thursday, 18'th Jun 2026
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies,
bioAffinity Technologies Announces Closing of $3.2 Million Offering
01:16pm, Thursday, 18'th Jun 2026
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $3.2 million offering.
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
10:41am, Wednesday, 17'th Jun 2026
JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
09:25am, Wednesday, 17'th Jun 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces pricing of a public offering.
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript
12:12am, Wednesday, 17'th Jun 2026
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces joint webinar with Philips and 4DMedical on diagnostic and imaging technologies to support lung health in veterans.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--The Society for Advanced Bronchoscopy to host June 16 webinar featuring CyPath Lung's role in detection and management of early-stage lung cancer.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies receives notice of allowance for Mexican patent on methods of predicting the likelihood of lung cancer using flow cytometry.
